Navigation Links
Valeant Pharmaceuticals Announces License Of ACZONE® (dapsone) Gel 5% In Canada
Date:2/8/2011

MISSISSAUGA, Ontario, Feb. 8, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement to license the Canadian rights to ACZONE® (dapsone) Gel 5%, a topical formulation of dapsone used in the treatment of acne vulgaris, from Allergan. Allergan will receive from BLS a CA$500,000 upfront payment to be followed by subsequent additional payments based on net sales.

"ACZONE® Gel is a strong addition to our Canadian business," said J. Michael Pearson, chief executive officer.  "This compound was originally approved in 2006 and never launched into the Canadian marketplace, providing Valeant Canada with a unique opportunity to strengthen and enhance our dermatology portfolio in Canada."

About ACZONE® Gel ACZONE® Gel is used to treat acne in patients 12 years of age and older. Acne is a skin condition characterized by the development of whiteheads, blackheads and other types of pimples. While acne can affect patients of any age, the condition is especially prevalent during adolescence.

Important Safety InformationACZONE® Gel is indicated for the topical treatment of acne vulgaris. ACZONE® Gel is not for oral, ophthalmic, or intravaginal use. ACZONE® Gel is contraindicated in patients who are hypersensitive to dapsone or to any ingredient in the formulation or component of the container.  Combination of ACZONE® Gel with trimethoprim/sulfamethoxazole (TMP/SMX) may increase the likelihood of hemolysis in patients with G6PD (glucose-6-phosphate dehydrogenase) deficiency.  The most common events reported from the clinical trials with ACZONE® Gel include oiliness/peeling, dryness, and erythema.  Serious adverse events reported in patients treated with ACZONE® Gel during clinical trials included but were not limited to severe pharyngitis, abdominal pain, severe vomiting, pancreatitis, suicide attempt, tonic clonic movements.

About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements, including, but not limited to, statements regarding growth opportunities for Valeant's Canadian dermatology portfolio. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission, which factors are incorporated herein by reference.  Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.Contact:Laurie W. LittleValeant Pharmaceuticals 949-461-6002(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Launches Senior Notes Offering
2. Valeant Pharmaceuticals to Acquire PharmaSwiss S.A.
3. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
4. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
5. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
6. Valeant Announces Pricing of Senior Notes
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
9. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
10. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
11. Valeant and Biovail Announce Results of Special Meetings of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 The key ... population, increasing diabetic population, accelerating economic growth and increasing healthcare ... industry are higher life expectancy of ESRD patients, rising demand ... markets. However, the expansion of the market is hindered by ... ...
(Date:3/23/2017)... N.C. , March 23, 2017  Transportation Insight, ... as an end-to-end supply chain management firm with expertise ... Consumer Product Solutions Rick Zaffarano was named ... of the Supply Chain by the only publication exclusively ... global food supply chain. "Rick has brought ...
(Date:3/23/2017)... and INDIANAPOLIS , March 23, 2017 ... ) and the William Sansum Diabetes Center have established ... people affected by diabetes through enhanced research, education and ... and cardiovascular disease bears a disproportionate weight on Latino ... said David Kerr , M.D., FRCPE, director of ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study ... because it does not obey the rules Congress has directed the CBO to follow. ... the GOP reform would restore. Yet, it estimates a reduction in employer-based coverage due ...
(Date:3/24/2017)... ... March 24, 2017 , ... The iaedp Foundation, the premier provider of educational ... those suffering from the full spectrum of disordered eating, announced today that the 2017 ... nearly all 50 states and several countries converged on the Green Valley Resort in ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer ... for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred Peru retreat ... This sacred and spiritual journey during the Summer Solstice will also be her ...
(Date:3/24/2017)... PA (PRWEB) , ... March 24, 2017 , ... ... Oncology Nursing Society (ONS) wanted to create a communications platform that positions them ... this goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. ... the Administrative Record, The majority of cases litigated under ERISA involve claims for ...
Breaking Medicine News(10 mins):